The real-life efficacy of fixed-dose hypomethylating agents in older patients with acute myeloid leukemia: A 10-year experience
This study focuses on the clinical outcome of various treatment protocols, including intensive chemotherapy, fixed-dose HMAs, and palliative treatment in Thai elderly patients with AML. Fixed-dose HMAs include 5-azacitidine given at 100 mg per day for seven days and decitabine given at 30 mg per day for five days.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tarinee Rungjirajittranon, Smith Kungwankiattichai, Chutima Kunacheewa, Weerapat Owatthanapanich Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Hematology | Leukemia | Lymphoma | Myeloma | Palliative | Study